Mylan climbs on talk of sale
The maker of generic and branded drugs for the nervous system broke out Wed. as rumors circulated on Twitter that Mylan (MYL) might be for sale, possibly to Teva Pharma (TEVA), and as it announced 3 drug launches. Analysts were divided about the logic of Teva buying Mylan, a competitor in generic drugs. Meanwhile, Mylan launched a pain medication in the U.S., a generic version of a drug used to treat opioid dependence, and a generic of Antabuse, used to treat alcoholism. Mylan shares rose 6.7% to 59. Teva rose 2.5% to 57.61.